TheStreet Ratings rates Johnson & Johnson (NYSE:JNJ) as a buy. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Johnson & Johnson (NYSE:JNJ) stock opened at $92.95 in last trading session, and closed at $92.42, trading in the range of $91.95 – $92.99. The stock showed a positive weekly performance of 5.89%.
Australia’s competition regulator said on Thursday it was taking legal action against the local division of Pfizer Inc. (NYSE:PFE)over the way it marketed its cholesterol-lowering drug Lipitor to pharmacies. The Australian Competition and Consumer Commision (AC) said Pfizer had, to deter competition, offered pharmacies “significant” discounts and rebates if they stocked at least a year’s worth of the drug, which goes by the generic name atorvastatin and is prescribed to over one million Australians. Pfizer Inc. (NYSE:PFE) shares closed at $31.61 on last trade day, by losing -0.85%. Stock 52 week range is $26.81 – $32.50. Company’s market capitalization is $204.87 billion.
Merck & Co (NYSE:MRK) Insider Willie Deese unloaded 50,000 shares of the company’s stock on the open market in a transaction dated Monday, February 10th. The shares were sold at an average price of $54.68, for a total transaction of $2,734,000.00. Following the transaction, the insider now directly owns 106,049 shares in the company, valued at approximately $5,798,759. Merck & Co., Inc. (NYSE:MRK) stock decreased -1.26% and finished the last session at $55.00. The EPS of the stock remained 1.48. Company’s market capitalization is $160.96 billion.
Equities research analysts at Jefferies Group lifted their price target on shares of Eli Lilly & Co. (NYSE:LLY) to $44.00 in a research note issued to investors on Wednesday, Stock Ratings Network reports. The firm currently has an “underperform” rating on the stock. Jefferies Group’s price objective indicates a potential downside of 19.28% from the company’s current price. Eli Lilly & Co. (NYSE:LLY) stock opened at $54.15 in last trading session and closed at $53.32. The 52 week range of the stock is $47.53 – $58.40 and the day range was $53.12 – $54.15.
Leave a Reply